A detailed history of Exodus Point Capital Management, LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 20,323 shares of IGMS stock, worth $169,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,323
Previous 453,898 95.52%
Holding current value
$169,290
Previous $3.79 Million 94.83%
% of portfolio
0.0%
Previous 0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$8.68 - $17.36 $3.76 Million - $7.53 Million
-433,575 Reduced 95.52%
20,323 $196,000
Q3 2023

Nov 09, 2023

BUY
$6.66 - $10.64 $3.02 Million - $4.83 Million
453,898 New
453,898 $3.79 Million
Q1 2023

May 11, 2023

BUY
$13.74 - $25.76 $172,711 - $323,803
12,570 Added 26.7%
59,650 $820,000
Q4 2022

Feb 13, 2023

BUY
$15.45 - $26.02 $333,642 - $561,901
21,595 Added 84.74%
47,080 $801,000
Q3 2022

Nov 10, 2022

BUY
$15.42 - $27.01 $392,978 - $688,349
25,485 New
25,485 $580,000
Q2 2022

Aug 19, 2022

SELL
$13.27 - $25.5 $142,360 - $273,564
-10,728 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$13.42 - $29.73 $22,787 - $50,481
1,698 Added 18.8%
10,728 $287,000
Q4 2021

Feb 11, 2022

BUY
$27.59 - $66.39 $107,683 - $259,120
3,903 Added 76.13%
9,030 $265,000
Q3 2021

Nov 15, 2021

SELL
$65.76 - $90.65 $109,556 - $151,022
-1,666 Reduced 24.53%
5,127 $337,000
Q2 2021

Aug 16, 2021

BUY
$57.98 - $96.6 $22,670 - $37,770
391 Added 6.11%
6,793 $565,000
Q1 2021

May 17, 2021

BUY
$71.56 - $121.23 $458,127 - $776,114
6,402 New
6,402 $491,000
Q4 2020

Feb 16, 2021

SELL
$47.41 - $115.03 $203,625 - $494,053
-4,295 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$43.0 - $84.01 $184,685 - $360,822
4,295 New
4,295 $317,000
Q2 2020

Aug 14, 2020

SELL
$51.3 - $75.21 $1.53 Million - $2.24 Million
-29,834 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$31.51 - $73.75 $940,069 - $2.2 Million
29,834 New
29,834 $1.68 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $241M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.